The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: A single center experience

Radiation Oncology

Volumn 11, Issue 1, 2016, Pages

  Ono, Takashi ^a   Hareyama, Masato ^b   Nakamura, Tatsuya ^a   Kimura, Kanako ^a   Hayashi, Yuichiro ^a   Azami, Yusuke ^a   Hirose, Katsumi ^a   Hatayama, Yoshiomi ^c   Suzuki, Motohisa ^a   Wada, Hitoshi ^a   Kikuchi, Yasuhiro ^a   Nemoto, Kenji ^d  

^a Southern Tohoku General Hospital   (Japan)

^b Sapporo Teishinkai Hospital   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

^d YAMAGATA UNIVERSITY   (Japan)

Author keywords

Idiopathic interstitial pneumonias; Idiopathic pulmonary fibrosis; Lung neoplasms; Protons; Radiation pneumonitis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; INCIDENCE; LUNG METASTASIS; LUNG TOXICITY; MALE; MIDDLE AGED; OXYGEN THERAPY; PNEUMONIA; PROTON THERAPY; RADIATION DOSE; RESPIRATORY FUNCTION DISORDER; RESPIRATORY GATED IMAGING; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY; BREATHING; IDIOPATHIC PULMONARY FIBROSIS; LUNG; LUNG NEOPLASMS; METASTASIS; PATHOLOGY; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; RADIATION PNEUMONITIS; RADIATION RESPONSE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROTON THERAPY; RADIATION PNEUMONITIS; RESPIRATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85007414758     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/S13014-016-0637-3     Document Type: Article

References (26)

1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277-304.
2. King Jr TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011; 378(9807):1949-61.
3. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000; 161(1):5-8.
4. Koizumi K, Hirata T, Hirai K, et al. Surgical treatment of lung cancer combined with interstitial pneumonia: the effect of surgical approach on postoperative acute exacerbation. Ann Thorac Cardiovasc Surg. 2004;10(6):340-6.
5. Kanzaki M, Kikkawa T, Maeda H, et al. Acute exacerbation of idiopathic interstitial pneumonias after surgical resection of lung cancer. Interact Cardiovasc Thorac Surg. 2011;13(1):16-20.
6. Sato T, Teramukai S, Kondo H, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014;147(5):1604-11.
7. Yamaguchi S, Ohguri T, Ide S, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82(2):260-5.
8. Yamashita H, Kobayashi-Shibata S, Terahara A, et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol. 2010;5:32.
9. Lee YH, Kim YS, Lee SN, et al. Interstitial lung change in pre-radiation therapy computed tomography is a risk factor for severe radiation pneumonitis? Cancer Res Treat. 2015. doi:10.4143/crt.2014.180.
10. Bush DA, Cheek G, Zaheer S, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and perIPFheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys. 2013; 86(5):964-8.
11. Chang JY, Komaki R, Lu C, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011;117(20):4707-13.
12. Nihei K, Ogino T, Ishikura S, Nishimura H. High-dose proton beam therapy for Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 65(1):107-11.
13. Kadoya N, Obata Y, Kato T, et al. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;79(4):1225-31.
14. Lee CH, Tait D, Nahum AE, Webb S. Comparison of proton therapy and conformal X-ray therapy in non-small cell lung cancer (NSCLC). Br J Radiol. 1999;72(863):1078-84.
15. Suit H, Goldberg S, Niemierko A, Trofimov A, Adams J, Paganetti H. Proton beams to replace photon beams in radical dose treatments. Acta Oncol. 2003;42(8):800-8.
16. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published May 28, 2009; Revised Version 4.03 June 14, 2010. [http://evs.nci. nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:8.5x11.pdf].
17. Hugh-Jones P, Lambert AV. A simple standard exercise test and its use for measuring exertion dyspnoea. Br Med J. 1952;1(4749):65-71.
18. Li Q, Swanick CW, Allen PK, et al. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol. 2014;112(2):256-61.
19. Yamashita H, Nakagawa K, Nakamura N, et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol. 2007;2:21.
20. Barriger RB, Forquer JA, Brabham JG, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2012;82(1):457-62.
21. Matsuo Y, Shibuya K, Nakamura M, et al. Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(4):e545-9.
22. Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012;13(7):671-8.
23. Yamamoto N, Nakagawa K, Nishimura Y, et al. Phase III study comparing second-and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010;28(23):3739-45.
24. Ley B, Collard HR, King Jr TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431-40.
25. Nagano T, Kotani Y, Fujii O, et al. A case of acute exacerbation of idiopathic pulmonary fibrosis after proton beam therapy for non-small cell lung cancer. Jpn J Clin Oncol. 2012;42(10):965-9.
26. Takeda A, Enomoto T, Sanuki N, et al. Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing. Radiat Med. 2008;26(8):504-7.